BioCardia, Inc.
384 Oyster Point Boulevard, #4
South San Francisco
California
94080
United States
Tel: 650-624-0120
Fax: 650-624-0125
Website: http://www.biocardia.com/
Email: hhall@biocardia.com
165 articles about BioCardia, Inc.
-
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
7/24/2023
BioCardia, Inc. today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP® Cell Therapy Heart Failure Trial.
-
BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study
6/20/2023
BioCardia®, Inc. [Nasdaq: BCDA] today announced that FDA Center for Biologics Evaluation and Research (CBER) has completed review of the CardiAMP Cell Therapy System adaptive statistical analysis design supplement for the ongoing pivotal study to treat ischemic heart failure with reduced ejection fraction (HFrEF).
-
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
6/8/2023
BioCardia®, Inc. today announces that the Japan Patent Office has granted Patent No: JP7282649B2 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on September 30, 2034.
-
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
5/23/2023
BioCardia®, Inc. today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place on July 12th.
-
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
5/10/2023
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission.
-
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications
5/9/2023
BioCardia®, Inc. announces that the United States Patent Office has granted Patent Number 11,642,377.
-
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
5/4/2023
BioCardia®, Inc. announced it will report its financial results for the three months ended March 31, 2023 and provide a corporate update by conference call on Wednesday, May 10, 2023 at 4:30 PM ET.
-
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
4/28/2023
BioCardia®, Inc. has made available two presentations from the “Next Generation Cardiovascular Drug Development Summit on Executing Cell and Gene Therapy for Cardiac Regeneration” which took place this week on April 26-27, 2023 in Boston, MA.
-
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
4/4/2023
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies.
-
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
3/29/2023
BioCardia®, Inc. today reported financial results for the year ended December 31, 2022 and filed its annual report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission.
-
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
3/16/2023
BioCardia ® , Inc. today announced it will report its financial results for the year ended December 31, 2022 and provide a corporate update conference call on Wednesday, March 29, 2023 at 4:30 PM ET.
-
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
3/6/2023
BioCardia®, Inc. [Nasdaq: BCDA] announces that detailed echocardiography data from the roll-in cohort of the Phase III CardiAMP® Cell Therapy Heart Failure Trial is being presented today at the American College of Cardiology annual meeting by Peter Johnston, M.D., Assistant Professor of Medicine and Site Principal Investigator at Johns Hopkins University.
-
BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
2/1/2023
BioCardia, Inc. today announce an amendment to their Clinical Research Supply and Support Agreement.
-
BioCardia Letter to Shareholders
12/22/2022
BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders.
-
BioCardia Announces $3.6 Million Private Placement of Common Stock
12/15/2022
BioCardia , Inc. today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with certain new and existing qualified institutional buyers, institutional accredited investors and certain directors and officers of the Company (the "Investors").
-
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
12/6/2022
BioCardia, Inc. today announced Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to initiate a first-in-human Phase I/II clinical trial of its Neurokinin-1 receptor positive (NK1R+) allogeneic human mesenchymal stem cell (MSC) therapy for the treatment of patients with ischemic heart failure.
-
BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
11/9/2022
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2022 with the United States Securities and Exchange Commission (SEC).
-
BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
11/2/2022
BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months ended September 30, 2022 and provide a corporate update by conference call on Wednesday, November 9, 2022 at 4:30 PM ET.
-
BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
9/9/2022
BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.
-
BioCardia to Participate in Cantor Fitzgerald’s Cell and Genetic Medicines Conference
9/8/2022
BioCardia®, Inc. announced it will participate on a panel as a presenting company at Cantor Fitzgerald’s Cell and Genetic Medicines Conference.